On-demand education
UROONCO RCC take home message for 2023
Dr. Agarwal shares LITESPARK-013 results: Optimal dose of belzutifan is 120mg
Prof. Roberto Iacovelli: Drug interruptions in mRCC IO-TKI (Avelumab and axitinib) is safe and may reduce toxicity and cost for the treatment
Prof. Albiges shares LITESPARK-005 study results: Belzutifan improves PFS in pretreated mRCC patients
Special series: 3D models for kidney cancer with caval thrombous
Impact of ERAS in Kidney cancer
Special series: Vascular perfusion 3D models and augmented reality for RCC surgery
Discussion with Prof. Badani at ERUS23 on RAPN
Prof. Kaouk talks about the novel single-port robotic platform
Surgical complications: An update from Prof. Kutikov on RPN risks
Management of metastatic kidney cancer
Practical aspects of cancer pathology for urologists. The 2023 WHO novelties
Dr. Antonelli talks about the retroperitoneal approach to RPN
Dr. Riccardo Bertolo and Dr. Alberto Breda talk about robotic surgery for kidney cancer
What treatment can be recommended in patients with local recurrence after partial nephrectomy